Literature DB >> 27391549

Biocompatibility of a Novel Microfistula Implant in Nonprimate Mammals for the Surgical Treatment of Glaucoma.

Thomas S Shute1, Ursula M Dietrich2, Julia F M Baker3, K Paige Carmichael4, William Wustenberg5, Iqbal Ike K Ahmed6, Arsham Sheybani1.   

Abstract

PURPOSE: The purpose of this study was to evaluate the ocular safety of a novel microfistula implant and its composite materials in an animal model.
METHODS: The anterior chambers of 12 rabbit eyes were injected with either glutaraldehyde cross-linked porcine gelatin extract or balanced salt solution and were followed by serial slit lamp examinations over 3 days. The eyes of 18 canines underwent microfistula implantation or a sham procedure. The animals were monitored over the subsequent 12 months, using serial slit lamp examinations, indirect ophthalmoscopy, tonometry, specular microscopy, and high-resolution ultrasonography. Ocular tissues were examined histopathologically on postoperative days 7, 30, 90, 180, and 365.
RESULTS: Glutaraldehyde cross-linked porcine gelatin did not induce significant intraocular inflammation in the rabbit model. The microfistula implant was well tolerated and did not stimulate significant tissue response in the canine eye. The microfistula tube did not undergo structural change or degradation over the course of the study.
CONCLUSIONS: In nonprimate mammals, the material composing the microfistula implant and the implant itself do not induce significant inflammation or tissue reaction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27391549     DOI: 10.1167/iovs.16-19453

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent.

Authors:  Alessandra De Gregorio; Emilio Pedrotti; Luisa Russo; Simonetta Morselli
Journal:  Int Ophthalmol       Date:  2017-05-29       Impact factor: 2.031

Review 2.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

3.  The Outcomes of XEN Gel Stent Implantation: A Systematic Review and Meta-Analysis.

Authors:  Xuan-Zhu Chen; Zhi-Qiao Liang; Kang-Yi Yang; Kun Lv; Yao Ma; Meng-Yang Li; Hui-Juan Wu
Journal:  Front Med (Lausanne)       Date:  2022-02-04

4.  Tissue Reactivity to, and Stability of, Glaucoma Drainage Device Materials Placed Under Rabbit Conjunctiva.

Authors:  Kenichi Nakamura; Tomokazu Fujimoto; Miho Okada; Kentaro Maki; Atsushi Shimazaki; Masatomo Kato; Toshihiro Inoue
Journal:  Transl Vis Sci Technol       Date:  2022-04-01       Impact factor: 3.283

Review 5.  XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice.

Authors:  A De Gregorio; E Pedrotti; G Stevan; A Bertoncello; S Morselli
Journal:  Clin Ophthalmol       Date:  2018-04-30

6.  Trabeculectomy versus Xen gel implant for the treatment of open-angle glaucoma: a 3-year retrospective analysis.

Authors:  Francesca Cappelli; Carlo Alberto Cutolo; Sara Olivari; Valeria Testa; Daniele Sindaco; Chiara Pizzorno; Sara Ciccione; Carlo Enrico Traaverso; Michele Iester
Journal:  BMJ Open Ophthalmol       Date:  2022-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.